Bifidobacterium Longum for IBS (Irritable Bowel Syndrome)

This pairing is unusual: the best trial of B. longum in IBS found its clearest benefit on mood rather than on bowel symptoms. If your IBS travels with anxiety or low mood, the case is more interesting than for IBS alone.

B. longum ferments oligosaccharides into acetate, supporting colonocyte energy supply and epithelial barrier integrity, and competitively excludes pathogens. In IBS specifically, animal models show reduced visceral hypersensitivity. The mood findings are attributed to vagal and microbial-metabolite signalling along the gut-brain axis, supported by the observed changes in amygdala and fronto-limbic activity on functional MRI.

The landmark study is a 2017 randomised, double-blind, placebo-controlled trial of B. longum NCC3001 in 44 adults with IBS and mild-to-moderate anxiety or depression. At six weeks, 64% of the probiotic group had a reduction of two or more points on the depression scale versus 32% on placebo, and functional MRI showed reduced limbic reactivity to negative emotional stimuli. IBS symptom severity improved numerically but did not reach significance for the primary bowel endpoint. Supporting evidence comes from multi-strain products containing B. longum, where overall IBS symptom scores improve modestly. Because those blends contain several organisms, the contribution of B. longum cannot be isolated. Weighing against it: 44 participants is small, the fMRI finding has not been independently replicated, and the work comes from a closely connected group of investigators with manufacturer involvement. The comparative case is also relevant — Bacillus coagulans and multi-strain formulations have more direct evidence for bowel symptoms.

People with constipation-predominant IBS, or those whose symptoms are clearly food-triggered, are unlikely to respond. Anyone with moderate or severe depression should be treated conventionally; a probiotic is not a substitute for care.